Borage oil attenuates progression of cardiac remodeling in rats after myocardial infarction
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2016
Editora
ACTA CIRURGICA BRASILEIRA
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
MALDONADO-MENETTI, Julianne dos Santos
VITOR, Taise
FERRANTE, Fernanda Ama
SOUZA, Pamella Ramona de Moraes
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
ACTA CIRURGICA BRASILEIRA, v.31, n.3, p.190-197, 2016
Resumo
PURPOSE: To investigate the effects of Borage oil on cardiac remodeling after myocardial infarction (MI). METHODS: Male Wistar rats underwent ligation of the left coronary artery and divided into three groups: MI (control), BO-18 (18 mg/kg of borage oil) and BO-180 (180 mg/kg of borage oil). After seven days, heart was arrested in diastole and processed for histological evaluation of: MI size, LV dilation, myocyte hypertrophy, inflammatory infiltration and fibrosis in MI region and in remote region. The relative weight of the lung was used as a marker of heart failure. The MI size was comparable among groups. RESULTS: Compared to control, BO treated groups showed lower weight of heart and lungs, reduced LV dilation and myocyte hypertrophy. Hemodynamic measurements were comparable. The treatment attenuated the inflammatory infiltration and fibrosis in remote myocardium. CONCLUSION: Borage oil attenuates progression of cardiac remodeling after myocardial infarction and congestive heart failure.
Palavras-chave
Myocardial Infarction, Ventricular Remodeling, Fatty Acids, Omega-6, Rats
Referências
- Amsterdam EA, 2014, J AM COLL CARDIOL, V64, pE139, DOI 10.1016/j.jacc.2014.09.017
- Laidlaw M, 2003, AM J CLIN NUTR, V77, P37
- Zornoff LAM, 2009, ARQ BRAS CARDIOL, V92, P157, DOI 10.1590/S0066-782X2009000200013
- Koike MK, 2007, INT J EXP PATHOL, V88, P279, DOI 10.1111/j.1365-2613.2007.00540.x
- Sette S, 2011, NUTR METAB CARDIOVAS, V21, P922, DOI 10.1016/j.numecd.2010.03.001
- Dooper MMBW, 2003, IMMUNOLOGY, V110, P348, DOI 10.1046/j.1365-2567.2003.01749.x
- Tanaka T, 2012, LIPIDS, V47, P643, DOI 10.1007/s11745-012-3664-3
- Machado RM, 2012, ATHEROSCLEROSIS, V224, P66, DOI 10.1016/j.atherosclerosis.2012.06.059
- Novak ML, 2013, J LEUKOCYTE BIOL, V93, P875, DOI 10.1189/jlb.1012512
- [Anonymous], 2012, IMMUNOLOGY
- FAN YY, 1992, J NUTR, V122, P1600
- Davidoff AW, 2004, ANN NY ACAD SCI, V1015, P84, DOI 10.1196/annals.1302.007
- Frimm CD, 1996, J MOL CELL CARDIOL, V28, P1279
- Furse RK, 2002, J CLIN IMMUNOL, V22, P83, DOI 10.1023/A:1014479702575
- la Paz SMD, 2014, J ETHNOPHARMACOL, V151, P131, DOI 10.1016/j.jep.2013.10.012
- Timmers L, 2007, CIRCULATION, V115, P326, DOI 10.1161/CIRCULATIONAHA.106.647230
- SANTOLI D, 1989, J IMMUNOL, V143, P1303
- Mills CD, 2000, J IMMUNOL, V164, P6166
- Marangoni F, 2014, ATHEROSCLEROSIS, V232, P334, DOI 10.1016/j.atherosclerosis.2013.11.048
- HORROBIN DF, 1992, PROG LIPID RES, V31, P163, DOI 10.1016/0163-7827(92)90008-7
- Santos R D, 2013, Arq Bras Cardiol, V100, P1, DOI 10.1590/S0066-782X2013000900001
- Frimm Clovis de Carvalho, 2003, Arq. Bras. Cardiol., V80, P515, DOI 10.1590/S0066-782X2003000500004
- Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
- SELYE H., 1960, ANGIOLOGY, V11, P398, DOI 10.1177/000331976001100505
- Simopoulos AP., 2008, ASIA PAC J CLIN NU S, V17, P131
- Wu JHY, 2014, CIRCULATION, V130, P1245, DOI 10.1161/CIRCULATIONAHA.114.011590